Allison R. Hanaford, Asheema Khanna, Katerina James, Vivian Truong, Ryan Liao, Yihan Chen, Michael Mulholland, Ernst‐Bernhard Kayser, Kino Watanabe, Erin Shien Hsieh, Margaret Sedensky, Philip G. Morgan, Vandana Kalia, Surojit Sarkar, Simon C. Johnson
AimLeigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi‐system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the Ndufs4(−/−) mouse model of LS: treatment of Ndufs4(−/−) mice with the macrophage‐depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon‐gamma (IFNγ) and interferon gamma‐induced protein 10 (IP10) were found to be significantly elevated in Ndufs4(−/−) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS.MethodsTo establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient Ndufs4(−/−)/Ifng(−/−) and Ndufs4(−/−)/IP10(−/−) double knockout animals, as well as IFNγ and IP10 heterozygous, Ndufs4(−/−)/Ifng(+/−) and Ndufs4(−/−)/IP10(+/−), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS.ResultsLoss of IP10 does not significantly impact the onset or progression of disease in the Ndufs4(−/−) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage‐dependent manner, though the benefits are modest compared to Csf1r inhibition.ConclusionsIFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.
目的利氏综合征(LS)是儿科最常见的遗传性线粒体功能障碍,是一种多系统疾病,以严重的神经和代谢异常为特征。脑干对称性、双侧进行性坏死是该病的显著特征。患者早期通常无症状,但一般在 2 岁左右出现症状。LS的发病和进展机制仍不清楚。最近的研究表明,在Ndufs4(-/-)LS小鼠模型中,免疫系统是疾病的诱因:用抑制巨噬细胞的Csf1r抑制剂pexidartinib治疗Ndufs4(-/-)小鼠可预防疾病。虽然导致免疫激活的确切机制和参与疾病进展的免疫因子尚未确定,但研究发现γ干扰素(IFNγ)和γ干扰素诱导蛋白10(IP10)在Ndufs4(-/-)脑干中显著升高,这表明这些因子与疾病有关。在此,我们旨在探讨IFNγ和IP10在LS中的作用。方法为了确定IFNγ和IP10在LS中的作用,我们产生了IFNγ和IP10缺失的Ndufs4(-/-)/Ifng(-/-)和Ndufs4(-/-)/IP10(-/-)双基因敲除动物,以及IFNγ和IP10杂合的Ndufs4(-/-)/Ifng(+/-)和Ndufs4(-/-)/IP10(+/-)动物。我们监测了疾病的发生和发展,以确定IFNγ和IP10的杂合或同源缺失对LS的影响。IFNγ的缺失以基因剂量依赖性的方式明显延长了生存期并延缓了疾病的进展,尽管与Csf1r抑制相比,其益处不大。我们的研究结果表明,IFNγ靶向疗法可能会给遗传线粒体疾病带来一些益处,但单独靶向 IFNγ 可能只会给 LS 带来适度的益处。
{"title":"Interferon‐gamma contributes to disease progression in the Ndufs4(−/−) model of Leigh syndrome","authors":"Allison R. Hanaford, Asheema Khanna, Katerina James, Vivian Truong, Ryan Liao, Yihan Chen, Michael Mulholland, Ernst‐Bernhard Kayser, Kino Watanabe, Erin Shien Hsieh, Margaret Sedensky, Philip G. Morgan, Vandana Kalia, Surojit Sarkar, Simon C. Johnson","doi":"10.1111/nan.12977","DOIUrl":"https://doi.org/10.1111/nan.12977","url":null,"abstract":"AimLeigh syndrome (LS), the most common paediatric presentation of genetic mitochondrial dysfunction, is a multi‐system disorder characterised by severe neurologic and metabolic abnormalities. Symmetric, bilateral, progressive necrotizing lesions in the brainstem are defining features of the disease. Patients are often symptom free in early life but typically develop symptoms by about 2 years of age. The mechanisms underlying disease onset and progression in LS remain obscure. Recent studies have shown that the immune system causally drives disease in the <jats:italic>Ndufs4</jats:italic>(−/−) mouse model of LS: treatment of <jats:italic>Ndufs4</jats:italic>(−/−) mice with the macrophage‐depleting Csf1r inhibitor pexidartinib prevents disease. While the precise mechanisms leading to immune activation and immune factors involved in disease progression have not yet been determined, interferon‐gamma (IFNγ) and interferon gamma‐induced protein 10 (IP10) were found to be significantly elevated in <jats:italic>Ndufs4</jats:italic>(−/−) brainstem, implicating these factors in disease. Here, we aimed to explore the role of IFNγ and IP10 in LS.MethodsTo establish the role of IFNγ and IP10 in LS, we generated IFNγ and IP10 deficient <jats:italic>Ndufs4</jats:italic>(−/−)/<jats:italic>Ifng</jats:italic>(−/−) and <jats:italic>Ndufs4</jats:italic>(−/−)/<jats:italic>IP10</jats:italic>(−/−) double knockout animals, as well as IFNγ and IP10 heterozygous, <jats:italic>Ndufs4</jats:italic>(−/−)/<jats:italic>Ifng</jats:italic>(+/−) and <jats:italic>Ndufs4</jats:italic>(−/−)/<jats:italic>IP10</jats:italic>(+/−), animals. We monitored disease onset and progression to define the impact of heterozygous or homozygous loss of IFNγ and IP10 in LS.ResultsLoss of IP10 does not significantly impact the onset or progression of disease in the <jats:italic>Ndufs4</jats:italic>(−/−) model. IFNγ loss significantly extends survival and delays disease progression in a gene dosage‐dependent manner, though the benefits are modest compared to Csf1r inhibition.ConclusionsIFNγ contributes to disease onset and progression in LS. Our findings suggest that IFNγ targeting therapies may provide some benefits in genetic mitochondrial disease, but targeting IFNγ alone would likely yield only modest benefits in LS.","PeriodicalId":19151,"journal":{"name":"Neuropathology and Applied Neurobiology","volume":"167 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-04-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140828331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Koji Yoshida, Shelley L. Forrest, Shojiro Ichimata, Hidetomo Tanaka, Tomoya Kon, Maria Carmela Tartaglia, Charles H. Tator, Anthony E. Lang, Naoki Nishida, Gabor G. Kovacs
AimsHirano bodies (HBs) are eosinophilic pathological structures with two morphological phenotypes commonly found in the hippocampal CA1 region in Alzheimer's disease (AD). This study evaluated the prevalence and distribution of HBs in AD and other neurodegenerative diseases.MethodsThis cross‐sectional study systematically evaluated HBs in a cohort of 193 cases with major neurodegenerative diseases, including AD (n = 91), Lewy body disease (LBD, n = 87), progressive supranuclear palsy (PSP, n = 36), multiple system atrophy (MSA, n = 14) and controls (n = 26). The prevalence, number and morphology of HBs in the stratum lacunosum (HBL) and CA1 pyramidal cell layer were examined. In addition, we investigated the presence of HBs in five additional hippocampal subregions.ResultsThe morphological types of HBs in CA1 were divided into three, including a newly discovered type, and were evaluated separately, with their morphology confirmed in three dimensions: (1) classic rod‐shaped HB (CHB), (2) balloon‐shaped HB (BHB) and the newly described (3) string‐shaped HB (SHB). The prevalence of each HB type differed between disease groups: Compared with controls, for CHB in AD, AD + LBD, PSP and corticobasal degeneration, for BHB in AD + LBD and PSP, and SHB in AD + LBD and PSP were significantly increased. Regression analysis showed that CHBs were independently associated with higher Braak NFT stage, BHBs with LBD and TDP‐43 pathology, SHBs with higher Braak NFT stage, PSP and argyrophilic grain disease and HBLs with MSA.ConclusionsThis study demonstrates that HBs are associated with diverse neurodegenerative diseases and shows that morphological types appear distinctively in various conditions.
{"title":"Revisiting the relevance of Hirano bodies in neurodegenerative diseases","authors":"Koji Yoshida, Shelley L. Forrest, Shojiro Ichimata, Hidetomo Tanaka, Tomoya Kon, Maria Carmela Tartaglia, Charles H. Tator, Anthony E. Lang, Naoki Nishida, Gabor G. Kovacs","doi":"10.1111/nan.12978","DOIUrl":"https://doi.org/10.1111/nan.12978","url":null,"abstract":"AimsHirano bodies (HBs) are eosinophilic pathological structures with two morphological phenotypes commonly found in the hippocampal CA1 region in Alzheimer's disease (AD). This study evaluated the prevalence and distribution of HBs in AD and other neurodegenerative diseases.MethodsThis cross‐sectional study systematically evaluated HBs in a cohort of 193 cases with major neurodegenerative diseases, including AD (<jats:italic>n</jats:italic> = 91), Lewy body disease (LBD, <jats:italic>n</jats:italic> = 87), progressive supranuclear palsy (PSP, <jats:italic>n</jats:italic> = 36), multiple system atrophy (MSA, <jats:italic>n</jats:italic> = 14) and controls (<jats:italic>n</jats:italic> = 26). The prevalence, number and morphology of HBs in the stratum lacunosum (HBL) and CA1 pyramidal cell layer were examined. In addition, we investigated the presence of HBs in five additional hippocampal subregions.ResultsThe morphological types of HBs in CA1 were divided into three, including a newly discovered type, and were evaluated separately, with their morphology confirmed in three dimensions: (1) classic rod‐shaped HB (CHB), (2) balloon‐shaped HB (BHB) and the newly described (3) string‐shaped HB (SHB). The prevalence of each HB type differed between disease groups: Compared with controls, for CHB in AD, AD + LBD, PSP and corticobasal degeneration, for BHB in AD + LBD and PSP, and SHB in AD + LBD and PSP were significantly increased. Regression analysis showed that CHBs were independently associated with higher Braak NFT stage, BHBs with LBD and TDP‐43 pathology, SHBs with higher Braak NFT stage, PSP and argyrophilic grain disease and HBLs with MSA.ConclusionsThis study demonstrates that HBs are associated with diverse neurodegenerative diseases and shows that morphological types appear distinctively in various conditions.","PeriodicalId":19151,"journal":{"name":"Neuropathology and Applied Neurobiology","volume":"19 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140630059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Karin Purshouse, Helen J. Bulbeck, Alasdair G. Rooney, Karen E. Noble, Ross D. Carruthers, Gerard Thompson, Petra Hamerlik, Christina Yap, Kathreena M. Kurian, Sarah J. Jefferies, Juanita S. Lopez, Michael D. Jenkinson, C. Oliver Hanemann, Lucy F. Stead
In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of funding, to be paralleled with £25m from Cancer Research UK, specifically for neuro‐oncology research over the subsequent 5 years. Herein, we review if and how the adult brain tumour research landscape in the United Kingdom has changed over that time and what challenges and bottlenecks remain. We have identified seven universal brain tumour research priorities and three cross‐cutting themes, which span the research spectrum from bench to bedside and back again. We discuss the status, challenges and recommendations for each one, specific to the United Kingdom.
{"title":"Adult brain tumour research in 2024: Status, challenges and recommendations","authors":"Karin Purshouse, Helen J. Bulbeck, Alasdair G. Rooney, Karen E. Noble, Ross D. Carruthers, Gerard Thompson, Petra Hamerlik, Christina Yap, Kathreena M. Kurian, Sarah J. Jefferies, Juanita S. Lopez, Michael D. Jenkinson, C. Oliver Hanemann, Lucy F. Stead","doi":"10.1111/nan.12979","DOIUrl":"https://doi.org/10.1111/nan.12979","url":null,"abstract":"In 2015, a groundswell of brain tumour patient, carer and charity activism compelled the UK Minister for Life Sciences to form a brain tumour research task and finish group. This resulted, in 2018, with the UK government pledging £20m of funding, to be paralleled with £25m from Cancer Research UK, specifically for neuro‐oncology research over the subsequent 5 years. Herein, we review if and how the adult brain tumour research landscape in the United Kingdom has changed over that time and what challenges and bottlenecks remain. We have identified seven universal brain tumour research priorities and three cross‐cutting themes, which span the research spectrum from bench to bedside and back again. We discuss the status, challenges and recommendations for each one, specific to the United Kingdom.","PeriodicalId":19151,"journal":{"name":"Neuropathology and Applied Neurobiology","volume":"43 1","pages":""},"PeriodicalIF":5.0,"publicationDate":"2024-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140570530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}